These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 20036196)

  • 1. Pathogenesis of Parkinson's disease: emerging role of molecular chaperones.
    Bandopadhyay R; de Belleroche J
    Trends Mol Med; 2010 Jan; 16(1):27-36. PubMed ID: 20036196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies.
    Ebrahimi-Fakhari D; Saidi LJ; Wahlster L
    Acta Neuropathol Commun; 2013 Dec; 1(1):79. PubMed ID: 24314025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular chaperones in Parkinson's disease--present and future.
    Ebrahimi-Fakhari D; Wahlster L; McLean PJ
    J Parkinsons Dis; 2011; 1(4):299-320. PubMed ID: 22279517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein Misfolding and Aggregation: The Relatedness between Parkinson's Disease and Hepatic Endoplasmic Reticulum Storage Disorders.
    Padilla-Godínez FJ; Ramos-Acevedo R; Martínez-Becerril HA; Bernal-Conde LD; Garrido-Figueroa JF; Hiriart M; Hernández-López A; Argüero-Sánchez R; Callea F; Guerra-Crespo M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein misfolding and aggregation in Parkinson's disease.
    Tan JM; Wong ES; Lim KL
    Antioxid Redox Signal; 2009 Sep; 11(9):2119-34. PubMed ID: 19243238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular chaperones and co-chaperones in Parkinson disease.
    Dimant H; Ebrahimi-Fakhari D; McLean PJ
    Neuroscientist; 2012 Dec; 18(6):589-601. PubMed ID: 22829394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggregopathy in neurodegenerative diseases: mechanisms and therapeutic implication.
    Dohm CP; Kermer P; Bähr M
    Neurodegener Dis; 2008; 5(6):321-38. PubMed ID: 18309232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular chaperones and Parkinson's disease.
    Hu S; Tan J; Qin L; Lv L; Yan W; Zhang H; Tang B; Wang C
    Neurobiol Dis; 2021 Dec; 160():105527. PubMed ID: 34626793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein degradation pathways in Parkinson's disease: curse or blessing.
    Ebrahimi-Fakhari D; Wahlster L; McLean PJ
    Acta Neuropathol; 2012 Aug; 124(2):153-72. PubMed ID: 22744791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collective roles of molecular chaperones in protein degradation pathways associated with neurodegenerative diseases.
    Luo GR; Le WD
    Curr Pharm Biotechnol; 2010 Feb; 11(2):180-7. PubMed ID: 20166963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.
    Sharma SK; Priya S
    Cell Mol Life Sci; 2017 Feb; 74(4):617-629. PubMed ID: 27522545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular chaperones and associated cellular clearance mechanisms against toxic protein conformers in Parkinson's disease.
    Hinault MP; Farina-Henriquez-Cuendet A; Goloubinoff P
    Neurodegener Dis; 2011; 8(6):397-412. PubMed ID: 21411979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of chaperones in Parkinson's disease and prion diseases.
    Winklhofer KF; Tatzelt J
    Handb Exp Pharmacol; 2006; (172):221-58. PubMed ID: 16610362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the Role of Ubiquitin-Proteasome System in Parkinson's Disease.
    Behl T; Kumar S; Althafar ZM; Sehgal A; Singh S; Sharma N; Badavath VN; Yadav S; Bhatia S; Al-Harrasi A; Almoshari Y; Almikhlafi MA; Bungau S
    Mol Neurobiol; 2022 Jul; 59(7):4257-4273. PubMed ID: 35505049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone.
    Lee JS; Kanai K; Suzuki M; Kim WS; Yoo HS; Fu Y; Kim DK; Jung BC; Choi M; Oh KW; Li Y; Nakatani M; Nakazato T; Sekimoto S; Funayama M; Yoshino H; Kubo SI; Nishioka K; Sakai R; Ueyama M; Mochizuki H; Lee HJ; Sardi SP; Halliday GM; Nagai Y; Lee PH; Hattori N; Lee SJ
    Brain; 2019 Sep; 142(9):2845-2859. PubMed ID: 31312839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase 6 regulates cytotoxic α-synuclein accumulation through induction of the heat shock response.
    Du Y; Wang F; Zou J; Le W; Dong Q; Wang Z; Shen F; Yu L; Li Y
    Neurobiol Aging; 2014 Oct; 35(10):2316-28. PubMed ID: 24866403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
    Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
    J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. alpha-synuclein degradation by autophagic pathways: a potential key to Parkinson's disease pathogenesis.
    Xilouri M; Vogiatzi T; Vekrellis K; Stefanis L
    Autophagy; 2008 Oct; 4(7):917-9. PubMed ID: 18708765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
    Mehra S; Sahay S; Maji SK
    Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.